跳至主要内容
临床试验/NCT00938262
NCT00938262已完成1 期

An Open-label, Three-treatment, Three-period, One-sequence, Crossover Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers

Boryung Pharmaceutical Co., Ltd0 个研究点目标入组 24 人开始时间: 2009年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
主要终点
Cmax, AUClast, AUCinf, CL/F, Tmax, t1/2

研究概览

简要总结

To evaluate the effect of ketoconazole and rifampicin on the pharmacokinetics of fimasartan.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • age: 20 - 45 years
  • sex: male
  • body weight: greater than 55 kg
  • written informed consent

排除标准

  • known allergy to Fimasartan, ketoconazole and rifampicin
  • existing cardiac or hematological diseases
  • existing hepatic and renal diseases
  • existing gastrointestinal diseases
  • acute or chronic diseases which could affect drug absorption or metabolism
  • history of any serious psychological disorder
  • positive drug or alcohol screening
  • smokers of 10 or more cigarettes per day 3 month ago
  • participation in a clinical trial during the last 2 months prior to the start of the study

研究组 & 干预措施

Fimasartan, Ketoconazole, Rifampicin

Experimental

干预措施: Fimasartan, Ketoconazole, Rifampicin (Drug)

结局指标

主要结局

Cmax, AUClast, AUCinf, CL/F, Tmax, t1/2

时间窗: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, (48, 56) h

次要结局

未报告次要终点

研究者

申办方类型
Industry

相似试验